Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Blacksmith who wrote (13888)	9/21/1998 1:22:00 PM
From: Peter Kerling	Read Replies (2) \| Respond to of 18691

SHORT Hemispherx BioPharma (HEB) Going to be published at the Sept‚mber, 28th edition of BusinessWeek: "But in recent days, the shares have pulled back a bit. A number of short-sellers are betting that the company's potential has been vastly overstated by the market. At issue is a drug called Ampligen, which the company believes is effective against chronic fatigue. Among the short-sellers is Manuel Asensio, head of investment boutique Asensio & Co. Asensio is shorting the stock with a target price of zero, having taken the view that Ampligen is neither safe nor effective. Asensio calls Ampligen ''a highly toxic, obsolete drug that is ineffective in the treatment of any disease.'' Hemispherx' CEO, Dr. William A. Carter, calls such assertions ''frivolous and wrong'' and says the drug's safety and effectiveness have been well established." Those of you who are not SHORT yet, GO! Peter